2,4-Bis<(2-methoxyethoxy)methoxy>benzaldehyd | 141330-16-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,4-Bis<(2-methoxyethoxy)methoxy>benzaldehyd
• 英文别名: 2,4-dimethoxyethoxymethyloxybenzaldehyde；2,4-bis(methoxyethoxymethoxy)benzaldehyde；2,4-Bis(2-methoxyethoxymethoxy)benzaldehyde
• CAS: 141330-16-7
• 化学式: C₁₅H₂₂O₇
• 分子量: 314.335
• InChiKey: DUAYXAHPCXNTSA-UHFFFAOYSA-N

物化性质

• 沸点：
  431.0±45.0 °C(Predicted)
• 密度：
  1.148±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  22
• 可旋转键数：
  13
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  72.4
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2,4-Bis<(2-methoxyethoxy)methoxy>benzaldehyd 在 Lipase Amano PS 、 potassium carbonate 、 间氯过氧苯甲酸 作用下， 以 正己烷 、 氯仿 、 乙酸乙酯 、 N,N-二甲基甲酰胺 、 丙酮 为溶剂， 反应 57.0h， 生成 (-)-(R)-5,7-dimethoxyethoxymethyloxy-2-acetoxymethyl-2,3-dihydrobenzofuran
  参考文献：
  名称：

  Enantioselective acylation of 2-hydroxymethyl-2,3-dihydrobenzofurans catalysed by lipase from Pseudomonas cepacia (Amano PS) and total stereoselective synthesis of (−)-(R)-MEM-protected arthrographol

  摘要：

  Lipase Amano PS catalysed acylation of (+/-)-2-hydroxymethyl-2,3-dihydrobenzofurans using vinyl acetate as the acyl donor in n-hexane gave (-)-(R)-2-acetoxymethyl-2,3-dihydrobenzo and (+)-(S)-2-hydroxymethyl-2,3-dihydrobenzofurans in high enantiomeric excess. (-)-(R)-Acetate 18j is converted to (-)-(R)-MEM-protected arthrographol 22. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(00)00302-5
• 作为产物：
  描述：

  (2,4-dihydroxy-benzylidene)-dimethyl-ammonium; dichloro phosphate 在 水 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.5h， 生成 2,4-Bis<(2-methoxyethoxy)methoxy>benzaldehyd
  参考文献：
  名称：

  Enantioselective acylation of 2-hydroxymethyl-2,3-dihydrobenzofurans catalysed by lipase from Pseudomonas cepacia (Amano PS) and total stereoselective synthesis of (−)-(R)-MEM-protected arthrographol

  摘要：

  Lipase Amano PS catalysed acylation of (+/-)-2-hydroxymethyl-2,3-dihydrobenzofurans using vinyl acetate as the acyl donor in n-hexane gave (-)-(R)-2-acetoxymethyl-2,3-dihydrobenzo and (+)-(S)-2-hydroxymethyl-2,3-dihydrobenzofurans in high enantiomeric excess. (-)-(R)-Acetate 18j is converted to (-)-(R)-MEM-protected arthrographol 22. (C) 2000 Published by Elsevier Science Ltd.

  DOI：

  10.1016/s0957-4166(00)00302-5

文献信息

• A thermally-stable enzyme detection assay that amplifies signal autonomously in water without assistance from biological reagents
  作者：Kimy Yeung、Kyle M. Schmid、Scott T. Phillips

  DOI：10.1039/c2cc36861g

  日期：——

  This Communication describes a thermally-stable small molecule and a corresponding assay strategy that autonomously amplifies a colorimetric signal when a specific enzyme biomarker is detected.

  本通讯介绍了一种热稳定小分子和相应的检测策略，当检测到特定酶生物标记物时，该策略可自主放大比色信号。
• Synthese und Reaktionsverhalten 2′-substituierter Isoflavone
  作者：Manfred Süsse、Siegfried Johne、Manfred Hesse

  DOI：10.1002/hlca.19920750205

  日期：1992.3.18

  Synthesis and Behaviour of Isoflavones Substituted in 2′-Position

  异黄酮在2′-位取代的合成及行为
• The first total synthesis of kwakhurin, a characteristic component of a rejuvenating plant, “kwao keur”: toward an efficient synthetic route to phytoestrogenic isoflavones
  作者：Fumihiro Ito、Misako Iwasaki、Toshiko Watanabe、Tsutomu Ishikawa、Yoshihiro Higuchi

  DOI：10.1039/b414955f

  日期：——

  A convergent synthesis of kwakhurin (5), a characteristic estrogen-like isoflavone of Pueraria mirifica(Leguminosae), is described. Isoflavone skeleton 31 was constructed by Suzuki-Miyaura coupling of 3-bromochromone 26 (AC-ring) and arylboronic acid 30 (B-ring) in the presence of TBAB as an additive. Microwave-assisted coupling was also examined, but did not improve the yield. Baeyer-Villiger oxidation

  描述了川w（5）的会聚合成，川w（5）是一种葛根的特征性雌激素样异黄酮。异黄酮骨架31是在TBAB作为添加剂的情况下，通过3-溴色酮26（AC环）和芳基硼酸30（B环）的Suzuki-Miyaura偶联反应构建的。还检查了微波辅助耦合，但没有提高产量。BAeyer-Villiger氧化，然后进行炔丙基化和还原，得到1,1-二甲基烯丙基醚37。通过在N，N-二乙基苯胺中37位的克莱森重排，以高收率获得了6'-Prenylisoflavone 34。另一方面，异戊二烯基醚33与粘土的1，3-重排使34的收率差。连续的34甲基化和脱保护，从2,4-二羟基苯甲醛（23）的总产率中，以12％的总收率获得了目标川葵素（5）。
• Breast cancer resistance protein (bcrp) inhibitor
  申请人：Yamazaki Ryuta

  公开号：US20060128636A1

  公开（公告）日：2006-06-15

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (—NHCOCH 3 group); a cyano group (—CN group); a formyl group (—CHO group), —COOR 1 (R 1 is hydrogen or C1-C4 alkyl), —O(CH 2 ) n COOR 2 (n=1−7: R 2 is hydrogen or C1-C4 alkyl), —OOCCH 2 CH 2 COOR 3 (R 3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., —OP(O) (OH) 2 ) or a salt thereof, a sulfate group (i.e., —OSO 3 H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制BCRP的药物。一种含有以下式（1）所表示的二苯乙烯腈衍生物作为活性成分的乳腺癌耐药蛋白抑制剂：[其中，8个R分别表示氢原子、羟基、硝基、氨基、乙酰氨基（—NHCOCH3基）、氰基（—CN基）、甲酰基（—CHO基）、—COOR1（R1为氢或C1-C4烷基）、—O（CH2）nCOOR2（n = 1-7：R2为氢或C1-C4烷基）、—OOC COOR3（R3为氢、C1-C4烷基、（Z）-2-（3,4-二甲氧基苯基）-3-（4-羟基苯基）-丙烯腈或葡萄糖基）、C1-C8烷氧基、C1-C4烷基、卤原子、C1-C4烷氧基C1-C4烷氧基C1-C4烷氧基、C2-C8酰氧基、C2-C8卤代酰氧基、亚甲二氧基基团、三氟甲基基团、磷酸酯基团（即—OP（O）（OH）2）或其盐、硫酸酯基团（即—OSO3H）或其盐、葡萄糖基或其盐、葡萄糖基的磷酸酯或酯的盐、葡萄糖基的硫酸酯或酯的盐，或者是它的酯或盐。
• BREAST CANCER RESISTANCE PROTEIN (BCRP) INHIBITOR
  申请人：KABUSHIKI KAISHA YAKULT HONSHA

  公开号：EP1591117A1

  公开（公告）日：2005-11-02

  The invention provides a drug which inhibits BCRP. A breast cancer resistance protein inhibitor containing, as an active ingredient, a diphenylacrylonitrile derivative represented by the following formula (1): [wherein, each of 8 R's, which are the same or different from one another, represents a hydrogen atom, a hydroxyl group, a nitro group, an amino group, an acetylamino group (-NHCOCH3 group), a cyano group (-CN group), a formyl group (-CHO group), -COOR1 (R1 is hydrogen or C1-C4 alkyl) , -O(CH2)nCOOR2 (n=1-7: R2 is hydrogen or C1-C4 alkyl) , -OOCCH2CH2COOR3 (R3 is hydrogen, C1-C4 alkyl, (Z)-2-(3,4-dimethoxy-phenyl)-3-(4-hydroxy-phenyl)-acrylonitrile, or glycopyranosyl), a C1-C8 alkoxy group, a C1-C4 alkyl group, a halogen atom, a C1-C4 alkoxy C1-C4 alkoxy C1-C4 alkoxy group, a C2-C8 acyloxy group, a C2-C8 halogenoacyloxy group, a methylenedioxy group, a trifluoromethyl group, a phosphate group (i.e., -OP(O) (OH)2) or a salt thereof, a sulfate group (i.e., -OSO3H) or a salt thereof, a glycopyranosyl group or a salt thereof, a phosphate ester of a glycopyranosyl group or a salt of the ester, a sulfate ester of a glycopyranosyl group or a salt of the ester, or a piperidinopiperidinocarbonyloxy group], an ester thereof, or a salt thereof.

  本发明提供了一种抑制 BCRP 的药物。 一种乳腺癌抗性蛋白抑制剂，其活性成分含有下式（1）所代表的二苯基丙烯腈衍生物： [其中，8 个彼此相同或不同的 R 的每一个代表氢原子、羟基、硝基、氨基、乙酰氨基（-NHCOCH3 基）、氰基（-CN 基）、甲酰基（-CHO 基）、-COOR1（R1 是氢或 C1-C4 烷基）、-O(CH2)nCOOR2（n=1-7：R2是氢或C1-C4烷基），-OOC COOR3（R3是氢、C1-C4烷基、(Z)-2-(3,4-二甲氧基苯基)-3-(4-羟基苯基)-丙烯腈或吡喃糖基），C1-C8烷氧基，C1-C4烷基、C1-C4 烷氧基、C2-C8 酰氧基、C2-C8 卤代酰氧基、亚甲基二氧基、三氟甲基、磷酸基团（即e.,-OP(O)(OH)2）或其盐、硫酸基（即-OSO3H）或其盐、吡喃糖基或其盐、吡喃糖基的磷酸酯或其酯盐、吡喃糖基的硫酸酯或其酯盐、哌啶基哌啶羰基氧基]、其酯或其盐。